We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Minoxidil — topical (Rogaine) & low-dose oral (LDOM) for hair loss
A potassium-channel-opening vasodilator — originally an oral antihypertensive — whose well-documented hypertrichosis side effect made it the first FDA-approved hair-loss drug. Topical 2–5% (Rogaine) is OTC and proven in androgenetic alopecia; low-dose ORAL minoxidil (LDOM, ~0.25–5 mg) is an off-label, rapidly adopted alternative with real but generally mild cardiovascular/hypertrichosis side effects. A drug, not a supplement — and not a longevity compound.
Prescription medication — not a dietary supplement
Minoxidil (oral & topical) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Minoxidil (oral & topical) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1976–2026 with a typical study size of 634 participants.
Based on 200 studies · 25 meta-analyses · 140 RCTs · 2,292 total participants
Confidence
High confidenceBy outcome
Topical minoxidil has FDA-grade double-blind RCT evidence for androgenetic alopecia in both men and women, and low-dose oral minoxidil now has supportive head-to-head RCT, meta-analysis, and large safety-cohort data — but it is a suppressive treatment (benefit reverses on stopping), the oral route is off-label with real systemic vasodilator side effects (hypertrichosis, fluid retention, tachycardia), and it is a hair-loss drug, not a longevity compound.
157 randomised trials
82% were about Minoxidil (oral & topical) in an audit of 50 of them
Every randomised or controlled trial of Minoxidil (oral & topical) indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
7 trials ongoing or recruiting · 3 completed on ClinicalTrials.gov
Registered trials show research momentum for Minoxidil (oral & topical), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Minoxidil is a potassium-ATP (K-ATP) channel opener that was developed as a potent oral antihypertensive (Loniten). Its near-universal side effect — hypertrichosis, unwanted body-hair growth — was repurposed into the first FDA-approved treatment for pattern hair loss.
Minoxidil is a prodrug: scalp sulfotransferase enzymes convert it to the active minoxidil sulfate, which opens K-ATP channels, promotes dermal-papilla vasodilation/perfusion, and prolongs the anagen (growth) phase of the hair follicle — which is why sulfotransferase activity partly predicts who responds.
Topical minoxidil 2% and 5% (solution or foam) is OTC-approved and supported by large double-blind RCTs in men and women: 5% outperforms 2% in men (Olsen 2002) and the 5% foam works in both sexes (a head-to-head trial found once-daily 5% foam numerically comparable to twice-daily 2% solution in women, though it did not formally meet its noninferiority margin).
The newer story is low-dose ORAL minoxidil (LDOM, typically 0.25–5 mg daily): off-label and Rx-only, it has been adopted rapidly because adherence is easier than twice-daily topical application.
A head-to-head RCT (Penha 2024, JAMA Dermatology) found no significant difference between oral 5 mg and topical 5% in one 68-person trial in men, with hypertrichosis in 49% on oral, and a meta-analysis of 4 oral-vs-topical RCTs found no significant difference in hair density but twice the hypertrichosis with oral (RR 2.01).
The honest framing: minoxidil genuinely regrows hair, but it is suppressive (benefit reverses on stopping), and oral dosing carries systemic effects from the same vasodilator mechanism — hypertrichosis is the most common reason for discontinuation, and fluid retention, lightheadedness, and tachycardia occur in a small percentage; the historical high-dose antihypertensive literature documents fluid retention and, rarely, pericardial effusion.
Large safety cohorts (Vañó-Galván 2021, n=1404; the hypertension/arrhythmia cohort) show LDOM is generally well tolerated at hair-loss doses, but it is a cardiovascular drug being used cosmetically, not a geroprotector.
The score reflects strong, FDA-grade efficacy evidence for topical and good emerging RCT/cohort evidence for oral, against a suppressive (lifelong) treatment model and real systemic side effects with the oral route.
Minoxidil is a prodrug — scalp sulfotransferase enzymes convert it to active minoxidil sulfate; sulfotransferase activity partly predicts who responds.
Minoxidil sulfate opens potassium-ATP channels, relaxing vascular smooth muscle — driving both dermal-papilla perfusion and the systemic blood-pressure effect.
Promotes a longer growth (anagen) phase and vellus-to-terminal hair conversion, increasing hair count and shaft diameter.
How Minoxidil (oral & topical) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Oral LDOM needs clinician oversight and dose titration; monitor for edema and tachycardia.
Oral minoxidil commonly causes facial/body hypertrichosis — set expectations; topical may be preferred.
Avoid — minoxidil is not recommended in pregnancy/lactation.
Additive blood-pressure lowering and fluid retention with oral minoxidil.
Oral minoxidil with guanethidine can cause profound orthostatic hypotension.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: From vasodilation; more common at higher oral doses — monitor weight/edema; a diuretic is sometimes co-prescribed.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment. Caution in those with cardiovascular disease.
Tip: Often the propylene-glycol vehicle — switching to 5% foam usually resolves it.
Tip: Documented mainly with high-dose antihypertensive use, not low-dose hair dosing; clinician monitoring if cardiac risk.
Minoxidil (oral & topical) has an evidence score of 5.5/10 — moderate evidence based on 200 indexed studies, including 1 meta-analysis. A potassium-channel-opening vasodilator — originally an oral antihypertensive — whose well-documented hypertrichosis side effect made it the first FDA-approved hair-loss drug. Topical 2–5% (Rogaine) is OTC and proven in androgenetic alopecia; low-dose ORAL minoxidil (LDOM, ~0.25–5 mg) is an off-label, rapidly adopted alternative with real but generally mild cardiovascular/hypertrichosis side effects. A drug, not a supplement — and not a longevity compound. Representative study: PMID 39425514.
Dosing for Minoxidil (oral & topical): Topical 2–5% solution or 5% foam applied to the scalp (men: 5% twice daily or once-daily foam; women: 2% twice daily or 5% foam once daily). Low-dose ORAL minoxidil is off-label and clinician-titrated, typically 0.25–5 mg once daily. A drug — not an approved supplement regimen. Individual needs vary, so check the right dose for you with a healthcare provider.
The best time to take Minoxidil (oral & topical) is in the morning. It can be taken on an empty stomach. Oral LDOM is taken once daily and is clinician-titrated from a low dose; topical is applied to a dry scalp once or twice daily and left on.
Minoxidil (oral & topical) should be used with caution — talk to a healthcare provider before taking it. Reported side effects include pericardial effusion, fluid retention / ankle edema, lightheadedness / tachycardia. How often they occur is not established for all of them. Use caution if any of these apply to you: Pheochromocytoma (oral — vasodilator); Significant uncontrolled cardiovascular disease without clinician oversight (oral); Known hypersensitivity to minoxidil or vehicle (e.g., propylene glycol in some topicals).
Finasteride (topical)
Too few graded studiesThe same drug as oral finasteride, applied to the scalp — with a systemic-sparing claim that the pharmacokinetic data only partly supports.
Finasteride
Too few graded studiesA prescription 5α-reductase type-II inhibitor that lowers DHT to treat male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). The hair and prostate benefits are well-proven in large RCTs. The honest caveats are real and prominent: sexual side effects (erectile dysfunction, decreased libido) in a minority of men, a disputed but important 'post-finasteride syndrome' with persistent symptoms, and a depression/suicidality safety signal in pharmacovigilance data. It is NOT a longevity drug.
Dutasteride
Too few graded studiesA dual 5α-reductase (type I + II) inhibitor approved for benign prostatic hyperplasia and used off-label for male pattern hair loss. It suppresses DHT more deeply than finasteride (which blocks only type II), and at 2.5 mg (five times the approved dose) it beat finasteride for hair count in one 24-week trial. It carries the same sexual and mood side-effect concerns as finasteride — with a much longer half-life, so any persistent effects clear more slowly. A prescription drug, not a supplement, and not a longevity drug.
Ketoconazole (Nizoral)
Too few graded studiesAn imidazole antifungal best known as a topical shampoo (Nizoral, 1% OTC / 2% Rx). Topically it is well-evidenced for seborrheic dermatitis and dandruff by suppressing scalp Malassezia, and is used off-label in androgenetic alopecia, where it shows modest anti-inflammatory and anti-DHT scalp effects. ORAL ketoconazole is a different story: the FDA and EMA severely restricted it in 2013 after reports of fatal liver injury and adrenal suppression, so systemic use is now rare. Prescription drug, not a supplement — informational only.
Explore: Best supplements for Skin, Hair & Beauty
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 200 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research